Turoctocog Alfa News
Turoctocog Alfa currently has 0 news articles, with 12 predicted indications.
This page combines the AI-predicted indications for Turoctocog Alfa with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Novoeight can be used for all age groups.
- Evidence level: L5
- Predicted indications (12):
- symptomatic form of hemophilia in female carriers (50.0%)
- hemophilia (50.0%)
- primary release disorder of platelets (100.0%)
- pseudo-von Willebrand disease (100.0%)
- Glanzmann thrombasthenia (100.0%)
- Scott syndrome (100.0%)
- acquired coagulation factor deficiency (100.0%)
- bleeding diathesis due to a collagen receptor defect (99.9%)
- hemorrhagic disorder due to a constitutional thrombocytopenia (99.9%)
- flood factor deficiency (99.6%)
- thrombotic thrombocytopenic purpura (99.5%)
- hereditary thrombocytosis with transverse limb defect (99.5%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.